Medical/Pharmaceuticals

Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia

* Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles inHong Kong and filed request for marketing authorization for Mainland China  * Extension of Exclusive License and Distribution Agreement to include seven additional countries across East andS...

2024-09-23 15:00 1614

Huawei Launches Medical Technology Digitalization 2.0 Solution, Facilitating Precision Healthcare with AI

SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- At HUAWEI CONNECT 2024, Huawei teamed up with partners to launch the Medical Technology Digitalization 2.0 Solution at the healthcare session namedEnhancing Inclusivity to Amplify Healthcare Intelligence. This solution implements AI-assisted diagnosis and ...

2024-09-23 12:10 4289

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and th...

2024-09-23 07:38 1613

Summit of Whose Future? Girls Have the Answers: Leaders Must Listen

Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center of Summit of the Future  NEW YORK, Sept. 21, 2024 /PRNewswire/ -- Today in New York, more than 50 young women from around the world – including Nobel Prize Laureate Malala Yousafzai – gathered to take go...

2024-09-21 21:30 2376

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC  - * HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available inEurope for first-line treatment of ES- SCLC  - * HANSIZHUANG (serplulimab) ha...

2024-09-21 13:42 4252

Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results

YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its unaudited ...

2024-09-21 05:30 6910

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...

2024-09-20 20:30 1446

Kangpu Completed Bridging Clinical Study of KPG-818 in China

HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inHefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects inChina. The randomized, double-blind, placebo-controlled,...

2024-09-20 20:00 1964

CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001

SUZHOU, China, Sept. 20, 2024 /PRNewswire/ -- CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-0...

2024-09-20 16:28 1560

Frost & Sullivan grants the Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAU

SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held inShanghai from August 27 to 30, 2024 , co-hosted by LeadLeo. Based on research and analysis of the global...

2024-09-19 21:48 2143

Dr. Quarraisha Abdool Karim, Hideyo Noguchi Africa Prize Winner, Joins GHIT Fund Board of Directors

First Board Member from Africa TOKYO, Sept. 19, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is pleased to announce that Dr. Quarraisha Abdool Karim was elected and appointed to the Director of the GHIT Fund Board at the Council Meeting held onSeptember 9, 2024. Dr. A...

2024-09-19 21:23 1841

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...

2024-09-19 20:30 1085

NUS scientists discover novel approach to rejuvenate aged egg cells

Groundbreaking findings provide a proof-of-concept development of a non-invasive cell-based method to improve the quality of eggs from older females for IVF SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Researchers from the Mechanobiology Institute  (MBI) at the National...

2024-09-19 18:28 1620

Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology

EAST RUTHERFORD, N.J., Sept. 19, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that utilizes...

2024-09-19 18:00 1558

Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, tod...

2024-09-19 17:28 2027

Fullerton Health Unveils 2023 Sustainability Report, Strengthening Commitment to a Greener Future

SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Fullerton Health is proud to announce the launch of its 2023 Sustainability Report. Understanding the urgency of the climate agenda, FHG, in the second year of Sustainability reporting, has incorporated a carbon plan. In addition to highlighting the compa...

2024-09-19 16:45 1875

Hyphens Pharma Launches Ceradan® Advanced Hand Balm, Specially Designed for Hand Eczema

SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Today, Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce the launch of Ceradan® A...

2024-09-19 14:00 1787

MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil

New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 18, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building ...

2024-09-19 11:05 1225

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...

2024-09-19 09:00 4319

Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024

Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), ...

2024-09-19 08:00 4224
1 ... 22232425262728 ... 610